Restructuring and Related Activities

12 Months Ended

Dec. 28, 2025

Restructuring and Related Activities [Abstract]

Restructuring and Other Costs Disclosure [Text Block]

Restructuring and Other Costs

Restructuring and other costs in fiscal year 2025 primarily included charges associated with workforce reductions and facility consolidations in an effort to streamline operations, other exit costs, abandonments or associated asset write-downs, cost of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities.

In fiscal year 2025, severance actions associated with facility consolidations and cost reduction measures affected approximately 5% of the Company’s workforce.

Restructuring and other costs in fiscal years 2024 and 2023 primarily included charges for workforce reductions and facility consolidations, abandonments or associated asset write-downs, cost of terminating certain lease agreements or contracts, as well as costs associated with relocating facilities. Severance actions associated with facility consolidations and cost reduction initiatives were not material to the Company’s overall workforce in both fiscal years.

Restructuring and other costs, included in the selling, general and administrative expenses in the consolidated statements of operations, by segment are as follows:


	December 28, 2025		December 29, 2024		December 31, 2023
	(In thousands)
Life Sciences	$	15,552	$	4,532	$	6,203
Diagnostics	39,337		12,539		15,465
Corporate	1,043		383		4,933
	$	55,932	$	17,454	$	26,601

The following table summarizes the changes in the Company’s accrued restructuring balance for fiscal year 2025. The changes in accrued restructuring balance for fiscal years 2024 and 2023 were not material. Other amounts reported as restructuring and other costs during fiscal year 2025 in the accompanying statement of income have been summarized in the notes to the table. Remaining obligations related to these accounts are expected to be paid over the next 12 months and are included in the accrued expenses and other current liabilities in the consolidated balance sheets.


	(In thousands)








Balance at December 29, 2024	$	3,836
Net restructuring charges incurred in 2025 (a)	28,167
Payments	(14,210)

Balance at December 28, 2025	$	17,793

(a) Excludes $27.8 million of charges, principally $20.8 million for asset impairment and $0.8 million of lease abandonment charges in the Diagnostics segment and $6.2 million of lease abandonment charges in the Life Sciences segment.

REVVITY, INC. 10-K